Nerhadou International is the nutraceutical pioneer in the Middle East. It was established in 1996 by former vice president of (Bristol Myers Squibb) Egypt, the Middle East & Africa. It is capitalizing on international trade experience in introducing high-quality products to the Egyptian Market. Nerhadou is enforced by a group of professionals and consultants of multinational experience in both the pharmaceuticals & consumer goods industry and corporate management & finance.
Contact
23,24,25 6th Industrial Zone Extension, 6th of October City, Giza, Egypt
Tel: (+202) 3824 3180
Dr Mohsen Shalaby, President of Nerhadou, explains how he has built Egypt’s leading mineral supplement and nutraceuticals company from scratch within 25 years. He highlights Nerhadou’s innovative solutions and the…
The latest news from Egyptian healthcare and life sciences, including progress towards the launch of a massive new oncology hospital, why local manufacturer EIPICO is expanding into Kazakhstan, increased governmental…
Amgen has forged a solid position as one of the world’s largest independent biotechnology companies. With a market capitalisation of some USD 130 billion and 27 approved medicines, the US-based…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
Head of the Middle East region and GM for the Middle East & Africa affiliate, Basel Thaher outlines his 18-year career at Menarini and discusses the Italian family-run company’s footprint…
Speaking as GM and head of the Middle East, Turkey, and Africa region, Andrew Bird, who has since become Acino’s Interim Chief Executive Officer, discusses the Swiss company’s “being global…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
The memorandum of understanding includes the localization of manufacturing at EVA Pharma’s specialized and internationally accredited facility for the manufacture of immunosuppressants in the 10th of Ramadan City, Egypt, in…
Amira Younes of AbbVie UAE examines how the COVID-19 pandemic highlighted the need for new ways of thinking about delivering regulatory effectiveness and efficiency in the region, and for flexibility…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda.…
Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant…
See our Cookie Privacy Policy Here
